|
US6100024A
(en)
|
1991-02-08 |
2000-08-08 |
Promega Corporation |
Methods and compositions for nucleic acid detection by target extension and probe amplification
|
|
US5298422A
(en)
|
1991-11-06 |
1994-03-29 |
Baylor College Of Medicine |
Myogenic vector systems
|
|
US5256555A
(en)
|
1991-12-20 |
1993-10-26 |
Ambion, Inc. |
Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
|
|
US5605798A
(en)
|
1993-01-07 |
1997-02-25 |
Sequenom, Inc. |
DNA diagnostic based on mass spectrometry
|
|
AU7839594A
(en)
|
1993-09-20 |
1995-04-10 |
Regents Of The University Of Colorado, The |
Strategy for the production of rna from immobilized templates
|
|
US6096503A
(en)
|
1993-11-12 |
2000-08-01 |
The Scripps Research Institute |
Method for simultaneous identification of differentially expresses mRNAs and measurement of relative concentrations
|
|
FR2733762B1
(fr)
|
1995-05-02 |
1997-08-01 |
Genset Sa |
Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
|
|
US6251665B1
(en)
|
1997-02-07 |
2001-06-26 |
Cem Cezayirli |
Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
|
|
AU7863200A
(en)
|
1999-10-06 |
2001-05-10 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger rna
|
|
US20030165849A1
(en)
|
2000-11-28 |
2003-09-04 |
Biliang Zhang |
Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA
|
|
US20030154032A1
(en)
*
|
2000-12-15 |
2003-08-14 |
Pittman Debra D. |
Methods and compositions for diagnosing and treating rheumatoid arthritis
|
|
US8426194B2
(en)
|
2003-01-21 |
2013-04-23 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating VEGF expression
|
|
GB0316089D0
(en)
|
2003-07-09 |
2003-08-13 |
Xo Bioscience Ltd |
Differentiation method
|
|
EP1660631B1
(en)
*
|
2003-08-01 |
2013-04-24 |
Life Technologies Corporation |
Compositions and methods for purifying short rna molecules
|
|
US20140142290A1
(en)
|
2003-08-01 |
2014-05-22 |
Life Technologies Corporation |
Compositions and methods for preparing short rna molecules and other nucleicacids
|
|
US20050287539A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Emmanuel Labourier |
Methods and compositions for preparing capped RNA
|
|
US20080220471A1
(en)
|
2005-07-27 |
2008-09-11 |
Genentech, Inc. |
Vectors and Methods Using Same
|
|
US9012219B2
(en)
*
|
2005-08-23 |
2015-04-21 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
|
EP4174179B1
(en)
|
2005-08-23 |
2025-05-07 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
EP2010659B1
(en)
|
2006-04-14 |
2014-06-18 |
CellScript, Inc. |
Kits and methods for generating 5' capped RNA
|
|
CN101611145B
(zh)
|
2006-12-21 |
2013-08-14 |
诺维信股份有限公司 |
用于在细菌细胞中表达基因的修饰型信使rna稳定化序列
|
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
EP2451475A2
(en)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Self replicating rna molecules and uses thereof
|
|
NO3112467T3
(es)
|
2009-12-07 |
2018-07-14 |
|
|
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP2013539969A
(ja)
*
|
2010-09-21 |
2013-10-31 |
リボックス・ゲーエムベーハー |
カリシウイルスのｒｎａポリメラーゼによる、マイクロ波によって駆動されるｒｎａ重合
|
|
DE19177059T1
(de)
|
2010-10-01 |
2021-10-07 |
Modernatx, Inc. |
N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
|
|
WO2012068383A2
(en)
|
2010-11-19 |
2012-05-24 |
The Regents Of The University Of Michigan |
ncRNA AND USES THEREOF
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
BR112013029490A2
(pt)
|
2011-05-17 |
2019-09-24 |
Moderna Therapeutics Inc |
ácidos nucleicos projetados e métodos de uso dos mesmos para vertebrados não humanos
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2013130161A1
(en)
|
2011-12-14 |
2013-09-06 |
modeRNA Therapeutics |
Methods of responding to a biothreat
|
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
|
US20130165504A1
(en)
|
2011-12-21 |
2013-06-27 |
modeRNA Therapeutics |
Methods of increasing the viability or longevity of an organ or organ explant
|
|
LT3421601T
(lt)
*
|
2011-12-30 |
2020-01-10 |
Cellscript, Llc |
In vitro susintetintos ssrnr gamyba ir panaudojimas įvedimui į žinduolių ląsteles biologinio arba biocheminio poveikio sukėlimui
|
|
JP2015516143A
(ja)
|
2012-04-02 |
2015-06-08 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
EP2885419A4
(en)
|
2012-08-14 |
2016-05-25 |
Moderna Therapeutics Inc |
ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
|
|
US20150307542A1
(en)
|
2012-10-03 |
2015-10-29 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
SMT202200337T1
(it)
|
2012-11-26 |
2022-09-14 |
Modernatx Inc |
Rna modificato al livello del terminale
|
|
EP2931914A4
(en)
|
2012-12-13 |
2016-08-17 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR CHANGING THE CELL PHENOTYPE
|
|
EP2968391A1
(en)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
MX2015011944A
(es)
|
2013-03-14 |
2015-12-01 |
Shire Human Genetic Therapies |
Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
|
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
|
WO2014152966A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Methods for purification of messenger rna
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
EP2970948B1
(en)
|
2013-03-15 |
2018-12-26 |
GlaxoSmithKline Biologicals SA |
Rna purification methods
|
|
US10138507B2
(en)
|
2013-03-15 |
2018-11-27 |
Modernatx, Inc. |
Manufacturing methods for production of RNA transcripts
|
|
US20160017313A1
(en)
|
2013-03-15 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
|
US11377470B2
(en)
|
2013-03-15 |
2022-07-05 |
Modernatx, Inc. |
Ribonucleic acid purification
|
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
|
US10590161B2
(en)
|
2013-03-15 |
2020-03-17 |
Modernatx, Inc. |
Ion exchange purification of mRNA
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
EP3971287A1
(en)
|
2013-07-11 |
2022-03-23 |
ModernaTX, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
WO2015051214A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
EP3058082A4
(en)
|
2013-10-18 |
2017-04-26 |
ModernaTX, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
US20170173128A1
(en)
|
2013-12-06 |
2017-06-22 |
Moderna TX, Inc. |
Targeted adaptive vaccines
|
|
US9988612B2
(en)
|
2014-03-20 |
2018-06-05 |
The Board Of Regents Of The University Of Texas System |
T7 RNA polymerase variants with expanded substrate range and enhanced transcriptional yield
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
EP3521456B1
(en)
|
2014-06-10 |
2023-01-04 |
CureVac Manufacturing GmbH |
Methods and means for enhancing rna production
|
|
EP3157573A4
(en)
|
2014-06-19 |
2018-02-21 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
JP2017524357A
(ja)
|
2014-07-16 |
2017-08-31 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
キメラポリヌクレオチド
|
|
US20170202979A1
(en)
|
2014-07-17 |
2017-07-20 |
Modernatx, Inc. |
Terminal modifications of polynucleotides
|
|
US20180000953A1
(en)
|
2015-01-21 |
2018-01-04 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
CN108064307A
(zh)
|
2015-04-30 |
2018-05-22 |
库瑞瓦格股份公司 |
使用固定化的限制酶进行体外转录的方法
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
WO2017011773A2
(en)
|
2015-07-15 |
2017-01-19 |
Modernatx, Inc. |
Codon-optimized nucleic acids encoding antibodies
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
EP4218805A1
(en)
|
2015-07-21 |
2023-08-02 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
US12150980B2
(en)
|
2015-07-30 |
2024-11-26 |
Modernatx, Inc. |
Concatemeric peptide epitope RNAs
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
US20180237849A1
(en)
|
2015-08-17 |
2018-08-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
DK3350157T3
(da)
|
2015-09-17 |
2022-02-14 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
|
|
JP6990176B2
(ja)
|
2015-10-05 |
2022-02-03 |
モデルナティエックス インコーポレイテッド |
メッセンジャーリボ核酸薬物の治療投与のための方法
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
WO2017070613A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3003090A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Cancer vaccines
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
JP7687767B2
(ja)
|
2015-10-22 |
2025-06-03 |
モデルナティエックス インコーポレイテッド |
呼吸器合胞体ウイルスワクチン
|
|
JP7384512B2
(ja)
|
2015-10-22 |
2023-11-21 |
モデルナティエックス インコーポレイテッド |
広域インフルエンザウイルスワクチン
|
|
TW201729838A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
|
|
PT3718565T
(pt)
|
2015-10-22 |
2022-07-20 |
Modernatx Inc |
Vacinas contra vírus respiratórios
|
|
EP3364982A4
(en)
|
2015-10-22 |
2019-04-17 |
ModernaTX, Inc. |
VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
|
|
SG11201803365RA
(en)
|
2015-10-22 |
2018-05-30 |
Modernatx Inc |
Herpes simplex virus vaccine
|
|
PL3386484T3
(pl)
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
AU2016369612B2
(en)
|
2015-12-17 |
2023-06-01 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-CoA mutase
|
|
SI3394030T1
(sl)
|
2015-12-22 |
2022-04-29 |
Modernatx, Inc. |
Sestave za doziranje sredstev v celice
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
EP3402881B1
(en)
|
2016-01-13 |
2021-04-28 |
New England Biolabs, Inc. |
Thermostable variants of t7 rna polymerase
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
MY201498A
(en)
|
2016-05-18 |
2024-02-27 |
Modernatx Inc |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
WO2017201317A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
EP3458590B9
(en)
|
2016-05-18 |
2021-08-18 |
ModernaTX, Inc. |
Polynucleotides encoding -galactosidase a for the treatment of fabry disease
|
|
EP3458107B1
(en)
|
2016-05-18 |
2024-03-13 |
ModernaTX, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
ES2973443T3
(es)
|
2016-05-18 |
2024-06-20 |
Modernatx Inc |
Polinucleótidos que codifican galactosa-1-fosfato uridililtransferasa para el tratamiento de galactosemia de tipo 1
|
|
CN115837014A
(zh)
|
2016-05-18 |
2023-03-24 |
摩登纳特斯有限公司 |
编码松弛素的多核苷酸
|
|
MA45037A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polythérapie à base d'arnm pour le traitement du cancer
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
US20200085916A1
(en)
|
2016-05-18 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
|
WO2017201347A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
US12123030B2
(en)
|
2016-05-18 |
2024-10-22 |
Modernatx, Inc. |
Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
|
|
KR20220159479A
(ko)
|
2016-05-18 |
2022-12-02 |
모더나티엑스, 인크. |
인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
|
|
CA3027201A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN106244608B
(zh)
|
2016-08-08 |
2019-10-25 |
中国科学技术大学 |
诱导的t7 rna聚合酶
|
|
CN109937253B
(zh)
|
2016-09-14 |
2023-06-30 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
EP3532613A4
(en)
|
2016-10-26 |
2020-05-06 |
ModernaTX, Inc. |
METHOD AND COMPOSITIONS FOR RNA MAPPING
|
|
KR20190086681A
(ko)
|
2016-10-26 |
2019-07-23 |
모더나티엑스, 인크. |
면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
|
US11384352B2
(en)
|
2016-12-13 |
2022-07-12 |
Modernatx, Inc. |
RNA affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
MX2019009070A
(es)
|
2017-02-01 |
2019-10-30 |
Modernatx Inc |
Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
|
|
EP3577221A4
(en)
|
2017-02-01 |
2020-12-23 |
ModernaTX, Inc. |
Polynucleotide secondary structure
|
|
WO2018144082A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
EP3582790A4
(en)
|
2017-02-16 |
2020-11-25 |
ModernaTX, Inc. |
VERY POWERFUL IMMUNOGENIC COMPOSITIONS
|
|
WO2018157009A1
(en)
|
2017-02-24 |
2018-08-30 |
Modernatx, Inc. |
Nucleic acid-based therapy of muscular dystrophies
|
|
AU2018234828A1
(en)
|
2017-03-15 |
2019-09-19 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
US20200038499A1
(en)
|
2017-03-22 |
2020-02-06 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
MA49463A
(fr)
|
2017-04-26 |
2021-05-05 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
EP3645711A4
(en)
|
2017-06-30 |
2021-04-21 |
Codexis, Inc. |
T7 RNA POLYMERASE VARIANTS
|
|
WO2019018765A1
(en)
|
2017-07-21 |
2019-01-24 |
Modernatx, Inc. |
MODIFIED mRNA ENCODING PROPIONYL-COA-CARBOXYLASE AND USES THEREOF
|
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
|
WO2019036670A2
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
EFFECTIVE MRNA VACCINES
|
|
EP3668971B8
(en)
|
2017-08-18 |
2024-05-29 |
ModernaTX, Inc. |
Rna polymerase variants
|
|
US11866696B2
(en)
|
2017-08-18 |
2024-01-09 |
Modernatx, Inc. |
Analytical HPLC methods
|
|
US11744801B2
(en)
|
2017-08-31 |
2023-09-05 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019055807A1
(en)
|
2017-09-14 |
2019-03-21 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZIKA VIRUS
|
|
DK3703658T3
(da)
|
2017-10-31 |
2022-07-18 |
Astrazeneca Ab |
Lipidnanopartikler til administration af modificeret rna, der koder for et vegf-a-polypeptid
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
JP2021504445A
(ja)
|
2017-11-21 |
2021-02-15 |
モデルナティーエックス， インコーポレイテッド |
エプスタイン−バーウイルスワクチン
|
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
|
AU2019293244A1
(en)
|
2018-06-27 |
2021-02-11 |
Modernatx, Inc. |
Personalized cancer vaccine epitope selection
|
|
EP3863645A4
(en)
|
2018-09-13 |
2022-11-16 |
ModernaTX, Inc. |
MODIFIED mRNA FOR THE TREATMENT OF FAMILY PROGRESSIVE INTRAHEPATIC CHOLESTASIS DISORDERS
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
JP7410135B2
(ja)
|
2018-09-19 |
2024-01-09 |
モデルナティエックス インコーポレイテッド |
治療薬の細胞内送達のための化合物及び組成物
|
|
MA53652A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg de haute pureté et leurs utilisations
|
|
CN113271926A
(zh)
|
2018-09-20 |
2021-08-17 |
摩登纳特斯有限公司 |
脂质纳米颗粒的制备及其施用方法
|
|
AU2019374818A1
(en)
|
2018-11-07 |
2021-05-27 |
Modernatx, Inc. |
RNA cancer vaccines
|
|
KR20210135494A
(ko)
|
2019-01-31 |
2021-11-15 |
모더나티엑스, 인크. |
지질 나노입자의 제조 방법
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
AU2020224103A1
(en)
|
2019-02-20 |
2021-09-16 |
Modernatx, Inc. |
Rna polymerase variants for co-transcriptional capping
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
KR20210149727A
(ko)
|
2019-03-11 |
2021-12-09 |
모더나티엑스, 인크. |
유가식(fed-batch) 시험관내 전사 공정
|
|
US12070495B2
(en)
|
2019-03-15 |
2024-08-27 |
Modernatx, Inc. |
HIV RNA vaccines
|
|
CA3142352A1
(en)
|
2019-05-31 |
2020-12-03 |
Modernatx, Inc. |
Expanded t cell assay
|
|
EP4013865A4
(en)
|
2019-08-14 |
2023-08-23 |
ModernaTX, Inc. |
PROCEDURE FOR PURIFICATION OF DOWNSTREAM PRODUCTS OF IN VITRO TRANSCRIPTION
|
|
JP2022547313A
(ja)
|
2019-09-11 |
2022-11-11 |
モデルナティエックス インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
|
AU2020348860A1
(en)
|
2019-09-19 |
2022-04-07 |
Modernatx, Inc. |
Cap guides and methods of use thereof for RNA mapping
|
|
AR120080A1
(es)
|
2019-09-19 |
2022-02-02 |
Modernatx Inc |
Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
|
|
US20210217484A1
(en)
|
2020-01-10 |
2021-07-15 |
Modernatx, Inc. |
Variational autoencoder for biological sequence generation
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
MX2022009429A
(es)
|
2020-01-30 |
2022-08-25 |
Modernatx Inc |
Composiciones para la inmunizacion contra virus respiratorios.
|
|
CA3169669A1
(en)
|
2020-01-31 |
2021-08-05 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
IL295377A
(en)
|
2020-02-07 |
2022-10-01 |
Modernatx Inc |
sars-cov-2 mRNA domain vaccines
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
EP4149484A4
(en)
|
2020-05-15 |
2024-10-02 |
ModernaTX, Inc. |
RNA FORMULATIONS FOR HIGH VOLUME DELIVERY
|
|
EP4153238A4
(en)
|
2020-05-21 |
2024-12-18 |
ModernaTX, Inc. |
METHYLENE BLUE STABILIZED MRNA COMPOSITIONS
|
|
WO2021247817A1
(en)
|
2020-06-05 |
2021-12-09 |
Modernatx, Inc. |
Bacterial strains for dna production
|
|
CN116348147A
(zh)
|
2020-08-06 |
2023-06-27 |
摩登纳特斯有限公司 |
用于将有效载荷分子递送至气道上皮的组合物
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20230355743A1
(en)
|
2020-09-25 |
2023-11-09 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
WO2022150717A1
(en)
|
2021-01-11 |
2022-07-14 |
Modernatx, Inc. |
Seasonal rna influenza virus vaccines
|
|
JP2024503698A
(ja)
|
2021-01-15 |
2024-01-26 |
モデルナティエックス インコーポレイテッド |
変異型株ベースのコロナウイルスワクチン
|
|
US20240139309A1
(en)
|
2021-01-15 |
2024-05-02 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
US20240100145A1
(en)
|
2021-03-05 |
2024-03-28 |
Moderna TX, Inc. |
Vlp enteroviral vaccines
|
|
JP2024511346A
(ja)
|
2021-03-15 |
2024-03-13 |
モデルナティエックス インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２ ｍｒｎａドメインワクチンの治療的使用
|
|
EP4313072A1
(en)
|
2021-03-26 |
2024-02-07 |
ModernaTX, Inc. |
Pertussis vaccine
|
|
US20240383940A1
(en)
|
2021-03-31 |
2024-11-21 |
Moderna TX, Inc. |
Synthesis of trinucleotide and tetranucleotide caps for mrna production
|
|
WO2022212711A2
(en)
|
2021-04-01 |
2022-10-06 |
Modernatx, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
|
JP2024515035A
(ja)
|
2021-04-01 |
2024-04-04 |
モデルナティエックス インコーポレイテッド |
ｍＲＮＡによる抗体構造及びアイソタイプの粘膜発現
|
|
EP4322993A1
(en)
|
2021-04-13 |
2024-02-21 |
ModernaTX, Inc. |
Respiratory virus combination vaccines
|
|
JP2024514183A
(ja)
|
2021-04-13 |
2024-03-28 |
モデルナティエックス インコーポレイテッド |
エプスタイン－バーウイルスｍＲＮＡワクチン
|
|
WO2022221336A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory syncytial virus mrna vaccines
|
|
WO2022221440A1
(en)
|
2021-04-14 |
2022-10-20 |
Modernatx, Inc. |
Influenza-coronavirus combination vaccines
|
|
WO2022226277A1
(en)
|
2021-04-23 |
2022-10-27 |
Modernatx, Inc. |
Stabilized formulations
|
|
WO2022226318A1
(en)
|
2021-04-23 |
2022-10-27 |
Modernatx, Inc. |
Isoquinoline-stabilized lipid nanoparticle formulations
|
|
WO2022232585A1
(en)
|
2021-04-29 |
2022-11-03 |
Modernatx, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
EP4355761A1
(en)
|
2021-06-14 |
2024-04-24 |
ModernaTX, Inc. |
Mrna vaccines encoding flexible coronavirus spike proteins
|
|
US20240293534A1
(en)
|
2021-06-14 |
2024-09-05 |
Modernatx, Inc. |
Coronavirus glycosylation variant vaccines
|
|
US20240218353A1
(en)
|
2021-06-17 |
2024-07-04 |
Modernatx, Inc. |
Alternative rna purification strategies
|
|
WO2023283642A2
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus concatemeric vaccines
|
|
WO2023283645A1
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus domain vaccines
|
|
EP4366768A4
(en)
|
2021-07-09 |
2025-05-21 |
ModernaTX, Inc. |
Pan-human coronavirus vaccines
|
|
EP4381059A1
(en)
|
2021-08-02 |
2024-06-12 |
ModernaTX, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
|
US20250281418A1
(en)
|
2021-08-11 |
2025-09-11 |
Modernatx, Inc. |
Lipid nanoparticle formulations and methods of synthesis thereof
|
|
WO2023019181A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Sars-cov-2 lipid nanoparticle vaccine formulations
|
|
US20240368580A1
(en)
|
2021-08-13 |
2024-11-07 |
Modernatx, Inc. |
Multicolumn chromatography mrna purification
|
|
WO2023056401A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
|
|
US20250011798A1
(en)
|
2021-10-18 |
2025-01-09 |
Modernatx, Inc. |
Markerless dna production
|
|
JP2024540917A
(ja)
|
2021-10-18 |
2024-11-06 |
モデルナティエックス インコーポレイテッド |
組み換えタンパク質生産のためのカスタム株
|
|
EP4419082A1
(en)
|
2021-10-20 |
2024-08-28 |
ModernaTX, Inc. |
Drug product surrogate solutions
|
|
US20250362278A1
(en)
|
2021-11-01 |
2025-11-27 |
Modernatx, Inc. |
Mass spectrometry of mrna
|
|
EP4426855A1
(en)
|
2021-11-05 |
2024-09-11 |
ModernaTX, Inc. |
Methods of purifying dna for gene synthesis
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
US20250360194A1
(en)
|
2021-12-08 |
2025-11-27 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
|
US20250067729A1
(en)
|
2021-12-15 |
2025-02-27 |
ModrnaTX, Inc. |
Determination of encapsulation efficiency of lipid nanoparticles
|
|
WO2023132885A1
(en)
|
2022-01-04 |
2023-07-13 |
Modernatx, Inc. |
Methods of purifying dna for gene synthesis
|
|
WO2023137149A1
(en)
|
2022-01-14 |
2023-07-20 |
Modernatx, Inc. |
In vitro transcription dna purification and recycling
|
|
WO2023150256A1
(en)
|
2022-02-03 |
2023-08-10 |
Modernatx, Inc. |
Continuous precipitation for mrna purification
|
|
US20250235531A1
(en)
|
2022-02-09 |
2025-07-24 |
Modernatx, Inc. |
Mucosal administration methods and formulations
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
WO2023201204A1
(en)
|
2022-04-11 |
2023-10-19 |
Modernatx, Inc. |
Detection of mrna purity in a mixture
|
|
JP2025513874A
(ja)
|
2022-04-14 |
2025-04-30 |
モデルナティエックス インコーポレイテッド |
Ｒｎａポリメラーゼバリアント
|
|
US20250251391A1
(en)
|
2022-04-15 |
2025-08-07 |
Modernatx, Inc. |
Ribosomal engagement potency assay
|
|
WO2023212696A1
(en)
|
2022-04-29 |
2023-11-02 |
Modernatx, Inc. |
Lyophilized human cytomegalovirus vaccines
|
|
US20250340586A1
(en)
|
2022-05-17 |
2025-11-06 |
Modernatx, Inc. |
Preparation of highly concentrated mrna
|
|
EP4544074A1
(en)
|
2022-06-24 |
2025-04-30 |
ModernaTX, Inc. |
Methods of producing rna
|
|
US20250388963A1
(en)
|
2022-07-06 |
2025-12-25 |
Modernatx, Inc. |
Primer design for cell-free dna production
|
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
|
WO2024026005A1
(en)
|
2022-07-28 |
2024-02-01 |
Modernatx, Inc. |
Methods of rna purification
|
|
EP4565694A1
(en)
|
2022-08-01 |
2025-06-11 |
ModernaTX, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
|
EP4612301A1
(en)
|
2022-11-03 |
2025-09-10 |
ModernaTX, Inc. |
Chemical stability of mrna
|
|
WO2024123978A1
(en)
|
2022-12-08 |
2024-06-13 |
Modernatx, Inc. |
Ionizable lipids with malonate tails
|
|
EP4648793A1
(en)
|
2023-01-11 |
2025-11-19 |
ModernaTX, Inc. |
Personalized cancer vaccines
|
|
WO2024163465A1
(en)
|
2023-01-30 |
2024-08-08 |
Modernatx, Inc. |
Epstein-barr virus mrna vaccines
|